Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Researchers have successfully 3D printed insulin-producing human pancreas cells that could revolutionize treatment for Type 1 ...

The printed cells remained alive and functional in test tubes for up to three weeks, maintaining strong insulin responses to glucose and showing real potential for future clinical use, the researchers ...

Long-term follow-up data show that the preventive effects of short-term treatment with abatacept disappear after 4-5 years.

Ashish Patil stands at the forefront of this evolution, transforming logistics through innovation, decision intelligence, and ...

Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) has received an average rating of “Hold” from the twenty-two brokerages that are presently covering the firm, MarketBeat reports. Two ...

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast ...

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...

Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day.

Bristol-Myers Squibb is running a rigorous Phase 2/3 clinical trial on ozanimod, aiming to help children with moderate to severe ulcerative colitis who haven’t responded to conventional treatments.

The stock's rise snapped a four-day losing streak.